XML 64 R51.htm IDEA: XBRL DOCUMENT v3.23.3
Restatement (Tables)
12 Months Ended
Dec. 31, 2022
Accounting Changes and Error Corrections [Abstract]  
Summary of Adjustments summary of the adjustments as of and for the year ended December 31, 2022 included in the Explanatory Note of this Form 10-K/A.

 

 

 

For the year ended December 31, 2022

 

Dollars in thousands, except per share data

 

As Reported

 

 

Adjustments

 

 

As Restated

 

Net interest income

 

$

110,391

 

 

$

(5,824

)

(a)

$

104,567

 

Provision for loan losses

 

 

17,886

 

 

 

7,801

 

(b)

 

25,687

 

Income (loss) from continuing operations before income tax expense

 

 

35,821

 

 

 

(13,625

)

 

 

22,196

 

Income tax expense (benefit)

 

 

8,244

 

 

 

(3,045

)

(c)

 

5,199

 

Net income from continuing operations

 

$

27,577

 

 

$

(10,580

)

 

$

16,997

 

Basic and diluted earnings (loss) per common share from continuing operations

 

$

1.46

 

 

$

(0.56

)

 

$

0.90

 

 

 

 

As of December 31, 2022

 

Dollars in thousands

 

As Reported

 

 

Adjustments

 

 

As Restated

 

Loans held for investment, net of deferred fees and costs

 

$

2,399,092

 

 

$

 

 

$

2,399,092

 

Allowance for loan losses

 

 

(22,939

)

 

 

(7,801

)

(b)

 

(30,740

)

Accrued interest receivable

 

 

12,393

 

 

 

(824

)

(d)

 

11,569

 

Deferred tax asset, net

 

 

9,182

 

 

 

3,045

 

(c)

 

12,227

 

Other assets

 

 

19,175

 

 

 

(5,000

)

(a)

 

14,175

 

Total assets

 

$

3,141,045

 

 

$

(10,580

)

 

$

3,130,465

 

Total stockholders' equity

 

$

259,373

 

 

$

(10,580

)

 

$

248,793

 

 

 

 

 

 

 

 

 

 

 

(a) - Attributable to $65.7 million of specialty finance loans reported as nonaccrual (as restated), previously reported as accruing as of December 31, 2022. See Note 4 for restated disclosures.

 

(b) - Attributable to incremental specific reserves for specialty finance loans. See Note 4 for restated disclosures.

 

(c) - Deferred income tax benefit of 22.35% on pre-tax adjustments. See Note 17 for restated disclosures.

 

(d) - Related to reversal of accrued loan fees associated with adjustment (a).